News brief­ing: Pfiz­er on track to ear­ly '22 piv­otal read­out on he­mo­phil­ia A; Co­di­ak scales back IPO ex­pec­ta­tions

5 years ago
News Briefing

Medicxi splash­es more fund­ing in­to Jan­pix's STAT pro­tein de­grad­er pro­gram

5 years ago
Financing
R&D

Ven­rock takes the wrap off its first mi­cro­bio­me start­up, armed with $50M, a CEO from 23andMe and two founders from ...

5 years ago
Financing
Startups

Jim Al­li­son and Pam Shar­ma back a Cana­di­an AI up­start seek­ing to solve the tu­mor stro­ma puz­zle

5 years ago
R&D
AI

Jump­ing ahead of Mer­ck and oth­ers, Bris­tol My­ers de­clares a PD-1 first in NSCLC

5 years ago
R&D

Covid-19 roundup: Ab­bott re­veals new test­ing kit da­ta; An OCD drug shows pos­i­tive signs in mild cas­es

5 years ago
Coronavirus

BAR­DA chief turned whistle­blow­er Rick Bright re­signs from gov­ern­ment with one last broad­side against the Trump ...

5 years ago
People
Coronavirus

A2 Bio­ther­a­peu­tics nabs $71M-plus Se­ries B for se­lec­tive cell ther­a­py pipeline

5 years ago
Financing
Cell/Gene Tx

Roche joins Ab­b­Vie in step­ping on Ver­tex's turf, bet­ting $96M on an al­ter­na­tive CF ap­proach

5 years ago
Deals

Em­manuelle Char­p­en­tier and Jen­nifer Doud­na win the No­bel Prize for ground­break­ing CRISPR dis­cov­ery

5 years ago
People
R&D

Fac­ing broad push­back from in­dus­try, White House backs down on FDA's Covid-19 vac­cine guid­ance

5 years ago
FDA+
Coronavirus

Oc­cu­pied with im­munol­o­gy and can­cer, Mer­ck KGaA hands off os­teoarthri­tis drug to No­var­tis for €50M cash

5 years ago
Deals

News brief­ing: Ax­o­vant re­ports im­proved mo­tor func­tion in small Parkin­son's tri­al; Bain life sci­ences SPAC files for ...

5 years ago
News Briefing

Ta­laris Ther­a­peu­tics bags an­oth­er $115M to curb im­muno­sup­pres­sion in or­gan trans­plant pa­tients

5 years ago
Financing
R&D

No new guid­ance, but here's some ad­vice: FDA draws a line in the sand for Covid-19 vac­cine de­vel­op­ers

5 years ago
FDA+
Coronavirus

The lat­est Jen­nifer Doud­na start­up launch­es with a Bio­gen part­ner­ship and eyes on big tar­gets few CRISPR com­pa­nies ...

5 years ago
People
Startups

San­thera kicks idebenone DMD pro­gram to the curb af­ter PhI­II tri­al fails in­ter­im analy­sis

5 years ago
R&D

GSK, Vir cleared to leap in­to PhI­II, an­gling for a spot in the Covid-19 an­ti­body race led by Lil­ly, Re­gen­eron

5 years ago
R&D
Coronavirus

Trump of­fi­cials said in­dus­try did­n't want FDA's stricter vac­cine guid­ance, but the lead­ing de­vel­op­er says they nev­er ...

5 years ago
FDA+
Coronavirus

Covid-19 roundup: Mod­er­na re­port­ed­ly lack­ing enough mi­nor­i­ty par­tic­i­pants; Pfiz­er, BioN­Tech and Re­gen­eron sued for ...

5 years ago
Coronavirus

FDA hands Y-mAbs re­fusal to file let­ter in one of its pe­di­atric neu­rob­las­toma pro­grams

5 years ago
R&D
FDA+

Io­vance shares ham­mered on TIL ther­a­py fil­ing de­lay — al­though an­a­lysts aren't as both­ered

5 years ago
Cell/Gene Tx

Laid off from Im­muno­Gen, an ex-Gen­zyme and Shire ex­ec heads to an ARCH up­start

5 years ago
People
Financing

Am­gen posts up­beat as­sess­ment of PhII KRAS da­ta on AMG510 — but there's no clear pic­ture of what re­searchers saw

5 years ago
Bioregnum
R&D
First page Previous page 793794795796797798799 Next page Last page
A service from the Financial Times